Opko Health (OPK) Acquires Two New Phase 3 Products
Tweet
Share
E-mailGet Alerts OPK Hot Sheet
Up)Join SI Premium – FREE
Opko Health (NYSE: OPK) entered into a definitive agreement to acquire Cytochroma Inc. (Markham, Canada) whose lead products, both in phase 3 clinical trials, are Replidea™ (coded CTAP101 Capsules), a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen™, a non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft (MSFT) to Avoid Formal EU Probe Over $13B OpenAI Deal - Bloomberg
- Cerevel Therapeutics Holdings (CERE) Reports Positive Topline Results for Tavapadon
- AbbVie (ABBV) Reports Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis
Create E-mail Alert Related Categories
FDA, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
